Co-Delivery of Ylang Ylang Oil of and Oxaliplatin Using Intelligent PH-Sensitive Lipid-Based Nanovesicles for the Effective Treatment of Triple-Negative Breast Cancer
Overview
Chemistry
Molecular Biology
Authors
Affiliations
Smart pH-responsive niosomes loaded with either Oxaliplatin (Ox), Ylang ylang essential oil (Y-oil), or co-loaded with both compounds (Ox-Y) (Ox@NSs, Y@NSs, and Ox-Y@NSs, respectively) were formulated utilizing the thin film method. The developed nanocontainers had a spherical morphology with mean particle sizes lower than 170 nm and showed negative surface charges, high entrapment efficiencies, and a pH-dependent release over 24 h. The prepared pH-responsive niosomes' cytotoxicity was tested against the invasive triple-negative breast cancer (MDA-MB-231) cells, compared to free OX and Y-oil. All niosomal formulations loaded with Ox and/or Y-oil significantly improved cytotoxic activity relative to their free counterparts. The Ox-Y@NSs demonstrated the lowest IC50 (0.0002 µg/mL) when compared to Ox@NSs (0.006 µg/mL) and Y@NSs (18.39 µg/mL) or unloaded Ox (0.05 µg/mL) and Y-oil (29.01 µg/mL) In addition, the percentages of the MDA-MB-231 cell population in the late apoptotic and necrotic quartiles were profoundly higher in cells treated with the smart Ox-Y@NSs (8.38% and 5.06%) than those exposed to free Ox (7.33% and 1.93%) or Y-oil (2.3% and 2.13%) treatments. Gene expression analysis and protein assays were performed to provide extra elucidation regarding the molecular mechanism by which the prepared pH-sensitive niosomes induce apoptosis. Ox-Y@NSs significantly induced the gene expression of the apoptotic markers Tp53, Bax, and Caspase-7, while downregulating the antiapoptotic Bcl2. As such, Ox-Y@NSs are shown to activate the intrinsic pathway of apoptosis. Moreover, the protein assay ascertained the apoptotic effects of Ox-Y@NSs, generating a 4-fold increase in the relative protein quantity of the late apoptotic marker Caspase-7. Our findings suggest that combining natural essential oil with synthetic platinum-based drugs in pH-responsive nanovesicles is a promising approach to breast cancer therapy.
Hassan H, Sedky N, Nafie M, Mahdy N, Fawzy I, Fayed T Molecules. 2024; 29(22).
PMID: 39598716 PMC: 11596978. DOI: 10.3390/molecules29225327.
Fahmy S, Sedky N, Hassan H, Abdel-Kader N, Mahdy N, Amin M Pharmaceutics. 2024; 16(10).
PMID: 39458611 PMC: 11510476. DOI: 10.3390/pharmaceutics16101282.
Fawzy M, Hassan H, Sedky N, Nafie M, Youness R, Fahmy S Nanoscale Adv. 2024; .
PMID: 39309515 PMC: 11414826. DOI: 10.1039/d4na00488d.
Liposomal Formulations of Metallodrugs for Cancer Therapy.
Botter E, Caligiuri I, Rizzolio F, Visentin F, Scattolin T Int J Mol Sci. 2024; 25(17).
PMID: 39273286 PMC: 11394711. DOI: 10.3390/ijms25179337.
Sedky N, Mahdy N, Abdel-Kader N, Abdelhady M, Maged M, Allam A RSC Adv. 2024; 14(12):8583-8601.
PMID: 38487521 PMC: 10938292. DOI: 10.1039/d3ra08908h.